Fierce Biotech Names FogPharma a “Fierce 15” Biotech Company of 2023
FogPharma®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the industry.
“It is an honor to be among the elite Fierce 15 class of 2023,” said Mathai Mammen, M.D., Ph.D. “I am proud of the FogPharma team and the important work that this team has done on behalf of patients with devastating illness using a unique and powerful drug modality capable of modulating important intracellular targets. We are currently advancing our first program, betacatenin inhibitor FOG-001 for the potential treatment of a wide range of cancers, including colorectal cancer.”
“For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the ‘Fierce 15’ special report. To curate this list, we consider a diverse range of factors, including the robustness of their technology, partnerships, venture support and their competitive positioning within the market,” said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare. “Our special report celebrates innovation and creativity in the face of intense competition.”
About Fierce Biotech
Fierce Biotech is the biotech industry’s daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories.
About FogPharma®
FogPharma is a biopharmaceutical company pioneering the discovery and development of the Helicon™ therapeutics, which are small proteins capable of efficient cell-entry and modulating protein-protein interactions that may otherwise be challenging to drug. Through this novel modality, FogPharma aims to address the limitations of existing drug classes and achieve universal druggability – a world where no targets are off-limits to new medicines. Spun out of Harvard University by pioneering academic scientist and successful biotech company builder Dr. Gregory Verdine, FogPharma is advancing a broad pipeline of Helicon therapeutics against important and biologically validated cancer targets that have remained elusive to other approaches, with the goal of providing new targeted treatment options for significant cancer patient populations. In November 2022, FogPharma completed a $178 million Series D financing and has raised more than $360 million to date from leading life sciences investors. FogPharma is headquartered in Cambridge, Mass. For more information, please visit www.parabilismed.com.